Mesoblast Ltd Sponsored ADR

Mesoblast Ltd Sponsored ADR is a biotechnology company focused on developing regenerative medicine products and allogeneic, off-the-shelf cellular therapies. The company’s platform is built around mesenchymal lineage cell technology designed for use across severe inflammatory and immune-mediated conditions, as well as selected cardiovascular and spine-related disorders. Its current pipeline includes cell-based medicines intended for hospital and specialist care settings, reflecting a focus on complex diseases with limited treatment options. Mesoblast operates through research, development, and commercialization activities across multiple regions, including Australia, the United States, Singapore, and Switzerland. As an ADR, Mesoblast Ltd Sponsored ADR gives U.S. investors access to the company’s underlying ordinary shares while representing a global healthcare business centered on advanced cell therapy and regenerative medicine.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)

Employees

83

Headquarters

Melbourne, VIC, Australia

Website

www.mesoblast.com